FMP
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
4.99 USD
0 (0%)
TSVT Financial Statements
Year
2024
2023
2022
2021
CF from Operating Activities
-85M
-166.86M
-237.13M
-207.03M
Net Income
-57.25M
-217.57M
-254.15M
-292.21M
Depreciation & Amortization
7.1M
10.29M
11.53M
16.35M
Deferred Income Taxes
0
0
0
0
Stock Based Compensation
12.15M
32.16M
41.04M
54.63M
Change in Working Capital
3M
2.6M
-35.87M
13.33M
Accounts Receivable
0
0
0
0
Inventory
0
0
0
0
Accounts Payable
-4.4M
-423k
327k
-6k
Other Working Capital
7.4M
3.03M
-36.2M
13.34M
Other Non-Cash Items
-50M
5.66M
317k
869k
CF from Investing Activities
80.76M
43.86M
11.7M
15.41M
Investments in Property, Plant & Equipment
-707k
-13.87M
-22.84M
-19.57M
Net Acquisitions
0
0
-34.54M
0
Investment Purchases
-153.27M
-265.17M
-145.91M
0
Sales/Maturities of Investments
166.5M
322.9M
180.45M
34.99M
Other Investing Activites
68.24M
0
34.54M
-33M
CF from Financing Activities
417k
127.39M
166.23M
354.89M
Debt Repayment
0
0
0
0
Common Stock Issued
0
126.86M
165.53M
6.54M
Common Stock Repurchased
0
0
0
0
Dividends Paid
0
0
0
0
Other Financing Activites
417k
527k
696k
354.89M
Free Cash Flow
-85.7M
-180.72M
-259.98M
-226.61M
Operating Cash Flow
-85M
-166.86M
-237.13M
-207.03M
Capital Expenditures
-707k
-13.87M
-22.84M
-19.57M
Cash at Beginning of Period
76.68M
72.29M
163.27M
0
Cash at End of Period
72.86M
76.68M
104.06M
163.27M
Net Change In Cash
-3.82M
4.39M
-59.21M
163.27M
All figures are in USD.
